IL312556A - New peptides - Google Patents

New peptides

Info

Publication number
IL312556A
IL312556A IL312556A IL31255624A IL312556A IL 312556 A IL312556 A IL 312556A IL 312556 A IL312556 A IL 312556A IL 31255624 A IL31255624 A IL 31255624A IL 312556 A IL312556 A IL 312556A
Authority
IL
Israel
Prior art keywords
novel peptides
peptides
novel
Prior art date
Application number
IL312556A
Other languages
English (en)
Hebrew (he)
Inventor
Peter Ellmark
Karin H?GERBRAND
Mattias Levin
Anna S?Ll
Laura Varas
Schantz Laura Von
Original Assignee
Alligator Bioscience Ab
Peter Ellmark
Karin H?GERBRAND
Mattias Levin
Anna S?Ll
Laura Varas
Schantz Laura Von
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2204539.7A external-priority patent/GB202204539D0/en
Priority claimed from GBGB2212801.1A external-priority patent/GB202212801D0/en
Application filed by Alligator Bioscience Ab, Peter Ellmark, Karin H?GERBRAND, Mattias Levin, Anna S?Ll, Laura Varas, Schantz Laura Von filed Critical Alligator Bioscience Ab
Publication of IL312556A publication Critical patent/IL312556A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL312556A 2021-11-05 2022-11-04 New peptides IL312556A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB202115925 2021-11-05
GBGB2204539.7A GB202204539D0 (en) 2022-03-30 2022-03-30 Novel peptides
GBGB2212801.1A GB202212801D0 (en) 2022-09-02 2022-09-02 Novel peptides
PCT/EP2022/080861 WO2023079102A2 (en) 2021-11-05 2022-11-04 Novel peptides

Publications (1)

Publication Number Publication Date
IL312556A true IL312556A (en) 2024-07-01

Family

ID=84329469

Family Applications (1)

Application Number Title Priority Date Filing Date
IL312556A IL312556A (en) 2021-11-05 2022-11-04 New peptides

Country Status (9)

Country Link
US (3) US11873348B2 (https=)
EP (2) EP4426738A2 (https=)
JP (2) JP2024543043A (https=)
KR (2) KR20240114794A (https=)
AU (1) AU2022381977A1 (https=)
CA (1) CA3237463A1 (https=)
IL (1) IL312556A (https=)
MX (1) MX2024005508A (https=)
WO (2) WO2023079102A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240114794A (ko) * 2021-11-05 2024-07-24 엘리게이터 바이오사이언스 에이비 신규 펩티드
WO2024213533A1 (en) * 2023-04-13 2024-10-17 Alligator Bioscience Ab Combination therapies
CN117924468B (zh) * 2023-12-08 2024-09-20 南京大学 一种靶向登革热病毒ns1蛋白纳米抗体的制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
GB201115280D0 (en) * 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
WO2016172485A2 (en) * 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
US20190336615A1 (en) * 2017-01-27 2019-11-07 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
GB201820556D0 (en) 2018-12-17 2019-01-30 Alligator Bioscience Ab Novel polypeptides
CN113677703A (zh) * 2018-12-17 2021-11-19 鳄鱼生物科学公司 多肽
CN120383671A (zh) * 2019-09-30 2025-07-29 阿迪马布有限责任公司 被工程化用于优先轻链配对的ch1结构域变体和包括所述ch1结构域变体的多特异性抗体
KR20220103957A (ko) * 2019-10-23 2022-07-25 리브젠 바이오파마 홀딩스 리미티드 항-cd40 결합 분자 및 이를 포함하는 이중-특이적 항체
MX2022008524A (es) * 2020-01-09 2022-09-21 Biomunex Pharmaceuticals Anticuerpos multiespecificos que se unen tanto a linfocitos mait como a celulas tumorales.
KR20240114794A (ko) * 2021-11-05 2024-07-24 엘리게이터 바이오사이언스 에이비 신규 펩티드

Also Published As

Publication number Publication date
EP4426733A2 (en) 2024-09-11
US20240117074A1 (en) 2024-04-11
WO2023079102A3 (en) 2023-06-15
CA3237463A1 (en) 2023-05-11
US12448465B2 (en) 2025-10-21
US20260001961A1 (en) 2026-01-01
KR20240114794A (ko) 2024-07-24
MX2024005508A (es) 2024-09-18
JP2024542142A (ja) 2024-11-13
US20230312754A1 (en) 2023-10-05
WO2023079101A2 (en) 2023-05-11
WO2023079101A3 (en) 2023-06-15
WO2023079102A2 (en) 2023-05-11
JP2024543043A (ja) 2024-11-19
EP4426738A2 (en) 2024-09-11
KR20240099410A (ko) 2024-06-28
US11873348B2 (en) 2024-01-16
AU2022381977A1 (en) 2024-05-23

Similar Documents

Publication Publication Date Title
GB202017649D0 (en) Polypeptide
GB202007441D0 (en) Polypeptide
IL312556A (en) New peptides
IL288412A (en) peptides
IL299811A (en) polypeptide
GB201900443D0 (en) Cell-penetrating peptides
GB202115803D0 (en) Novel proteins
GB202019879D0 (en) Polypeptide
GB201918693D0 (en) Peptide
GB202209520D0 (en) Peptides
GB202117405D0 (en) Peptide
IL290019A (en) Peptides to regulate melanocytes
EP4333867C0 (en) COVID-19 BINDING PEPTIDE
GB202018608D0 (en) Adhesive peptides
GB202113858D0 (en) Peptides
GB202110693D0 (en) Peptides
GB202212801D0 (en) Novel peptides
GB202204539D0 (en) Novel peptides
GB202404497D0 (en) Peptides
GB202217153D0 (en) Peptides
GB202201768D0 (en) Peptides
GB202111675D0 (en) Peptide
GB202313820D0 (en) Peptide
GB202119034D0 (en) Polypeptide
GB201906982D0 (en) Peptides